An Open Label Extension Study of BMS-911543 In Subjects With Myelofibrosis


About this study

The purpose of this study is to provide patients with myleofibrosis (MF) who participated in study CA215001 access to BMS-911543.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Patients currently enrolled in study CA215001 and receiving benefit and tolerating BMS-911543.  NOTE: Patients will continue therapy at their doctor’s discretion until November 30, 2016 or until the patients develop progressive disease or unacceptable toxicity criteria, whichever occurs first.
  • Provide informed written consent.
  • Age ≥ 18 years 
  • Willing to return to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).

Exclusion Criteria:

  • Any of the following:
    • Pregnant women
    • Nursing women
    • Men or women of childbearing potential who are unwilling to employ adequate contraception

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Animesh Pardanani, M.B.B.S., Ph.D.

Closed for enrollment

Contact information:

Research Information Center


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer